These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31362918)

  • 1. The Hep B Calculator: an online tool for cost-effectiveness analyses of treatment.
    Toy M; Hutton DW; Lauer J; Bulterys M; Hutin Y; So S
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):668. PubMed ID: 31362918
    [No Abstract]   [Full Text] [Related]  

  • 2. A Convenient Truth: Cost of Medications Need Not Be a Barrier to Hepatitis B Treatment.
    Barnhart M
    Glob Health Sci Pract; 2016 Jun; 4(2):186-90. PubMed ID: 27353613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of oral treatments for chronic hepatitis B.
    Dusheiko GM
    J Hepatol; 2009 Oct; 51(4):623-5. PubMed ID: 19695728
    [No Abstract]   [Full Text] [Related]  

  • 4. Applicability of cost-effectiveness analysis to management of chronic hepatitis B.
    Dan YY; Lim SG
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1357-9. PubMed ID: 17716341
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of viral hepatitis B & C treatment.
    Toy M
    Best Pract Res Clin Gastroenterol; 2013 Dec; 27(6):973-85. PubMed ID: 24182615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antiviral therapies are cost-effective vs. no treatment but indirect comparisons should be avoided.
    Mantovani LG; de Portu S
    J Hepatol; 2009 Dec; 51(6):1086-7; author reply 1087-8. PubMed ID: 19853949
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
    Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
    Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economics of chronic hepatitis B and hepatitis C.
    Rajendra A; Wong JB
    J Hepatol; 2007 Oct; 47(4):608-17. PubMed ID: 17697724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral therapy for chronic hepatitis B: challenges in Hong Kong.
    Chan HL
    J Hepatol; 2009 Dec; 51(6):1088-90. PubMed ID: 19853951
    [No Abstract]   [Full Text] [Related]  

  • 10. Hep C Calculator: an online tool for cost-effectiveness analysis of DAAs.
    Chhatwal J; Chen Q; Bethea ED; Ladd MA; Mueller PP; Hutin Y; Aggarwal R
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):819. PubMed ID: 30507463
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
    Vanagas G; Padaiga Z; Mickevičienė A
    Medicina (Kaunas); 2010; 46(12):835-42. PubMed ID: 21532288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost-effectiveness of nucleoside/nucleotide analogues in chronic hepatitis B].
    Almeida AM; Silva AL; Brandão CM; Cherchiglia ML; Andrade EI; Araújo de Oliveira GL; Carmo RA; Acurcio Fde A
    Rev Saude Publica; 2012 Dec; 46(6):942-9. PubMed ID: 23503535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review.
    Buti M; Oyagüez I; Lozano V; Casado MA
    Pharmacoeconomics; 2013 Jan; 31(1):63-75. PubMed ID: 23329593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea].
    Kim BK; Kwon SY; Lee CH; Choe WH; Choi HM; Koo HW
    Korean J Hepatol; 2009 Mar; 15(1):25-41. PubMed ID: 19346783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness in hepatitis B.
    Weitzman G; Jacobson I
    Ann Intern Med; 2005 Nov; 143(10):757-8; author reply 758-9. PubMed ID: 16287803
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of chronic Hepatitis B in resource-constrained countries: an economic solution is required.
    Thomas H
    J Viral Hepat; 2013 Apr; 20 Suppl 1():2. PubMed ID: 23458518
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha.
    Babu S
    Natl Med J India; 2003; 16(3):175; author reply 175-6. PubMed ID: 12929872
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha.
    Desai HG
    Natl Med J India; 2003; 16(3):175; author reply 175-6. PubMed ID: 12929870
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence.
    Sun X; Qin WX; Li YP; Jiang XH
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1369-77. PubMed ID: 17716343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
    Sullivan SD; Veenstra DL; Chen PJ; Chang TT; Chuang WL; Tsai C; Patel K
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1494-9. PubMed ID: 17716353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.